<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase </plain></SENT>
<SENT sid="1" pm="."><plain>Overexpression of SKP2 was found in various human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>This study examined the correlation of SKP2 expression in the prognosis of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> patients and the viability of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells treated with CRT </plain></SENT>
<SENT sid="3" pm="."><plain>SKP2 immunoexpression was retrospectively assessed in pretreatment biopsies of 172 rectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients treated with neoadjuvant CRT followed by surgery </plain></SENT>
<SENT sid="4" pm="."><plain>Results were correlated with clinicopathological features, therapeutic responses, and patient survival </plain></SENT>
<SENT sid="5" pm="."><plain>Pharmacologic assays were used to evaluate the therapeutic relevance of <z:chebi fb="0" ids="52717">Bortezomib</z:chebi> in two <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines (HT-29 and SW480) </plain></SENT>
<SENT sid="6" pm="."><plain>High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Control stage (p = 0.002), and a lower-degree <z:mp ids='MP_0010537'>tumor regression</z:mp> grade (p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, high expression of SKP2 (p = 0.027, hazard ratio 3.21) was an independent prognostic factor for local recurrence-free survival </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro, <z:chebi fb="0" ids="52717">Bortezomib</z:chebi> downregulated SKP2 expression, induced caspase activation, and decreased the viability of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells with or without a combination with fluorouracil </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> also promoted caspase activation and gamma-H2AX formation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells concurrently treated with CRT </plain></SENT>
<SENT sid="10" pm="."><plain>High expression of SKP2 was associated with a poor therapeutic response and adverse outcomes in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> patients treated with neoadjuvant CRT </plain></SENT>
<SENT sid="11" pm="."><plain>In the presence of chemotherapy with or without radiotherapy, the promoted sensitivity of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to <z:chebi fb="0" ids="52717">Bortezomib</z:chebi> with an SKP2-repressing effect indicated that it is a potential therapeutic target </plain></SENT>
</text></document>